ORIC Pharmaceuticals, Inc. (ORIC) 

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Show less

Over the last 12 months, insiders at ORIC Pharmaceuticals, Inc. have bought $0 and sold $1.67M worth of ORIC Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at ORIC Pharmaceuticals, Inc. have bought $9.71M and sold $16.08M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 304,574 shares for transaction amount of $883,569 was made by Chacko Jacob (President and CEO) on 2022‑05‑11.